Insider Selling: Shattuck Labs (NASDAQ:STTK) Insider Sells $210,300.00 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) insider Arundathy Pandite sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total value of $210,300.00. Following the transaction, the insider directly owned 136,219 shares in the company, valued at $954,895.19. This trade represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shattuck Labs Price Performance

Shares of STTK opened at $7.05 on Friday. The firm has a market capitalization of $540.59 million, a PE ratio of -11.19 and a beta of 1.05. The firm has a 50-day moving average price of $5.96 and a 200 day moving average price of $5.27. Shattuck Labs, Inc. has a 52-week low of $0.71 and a 52-week high of $8.33.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter in the prior year, the company earned ($0.27) EPS. On average, equities analysts expect that Shattuck Labs, Inc. will post -0.51 EPS for the current year.

Institutional Trading of Shattuck Labs

A number of hedge funds have recently bought and sold shares of STTK. Virtu Financial LLC purchased a new position in shares of Shattuck Labs in the third quarter worth approximately $38,000. AQR Capital Management LLC lifted its position in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after acquiring an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs in the 2nd quarter worth approximately $44,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs during the 3rd quarter worth approximately $46,000. Finally, Bridgeway Capital Management LLC grew its position in Shattuck Labs by 147.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after purchasing an additional 55,000 shares in the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Shattuck Labs in a research report on Monday, June 8th. Jefferies Financial Group upgraded Shattuck Labs to an “outperform” rating and set a $7.00 price target on the stock in a research report on Friday, June 5th. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Citigroup upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, June 5th. Finally, Cantor Fitzgerald began coverage on Shattuck Labs in a report on Monday, April 27th. They set an “overweight” rating on the stock. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Shattuck Labs presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.